U
VIVO

UBS’s Meridian Bioscience Inc VIVO Stock Holding History

UBS’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$4K Sell
200
-400
-67% -$7.86K ﹤0.01% 9666
2014
Q2 		$12K Buy
600
+200
+50% +$4.11K ﹤0.01% 8714
2014
Q1 		$9K Buy
+400
New +$9.17K ﹤0.01% 9057

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

UBS's VIVO Position: Q3 2014 in Review

UBS increased its Meridian Bioscience Inc (VIVO) stake by 21% in Q3 2014, buying an estimated $25.7K and bringing the position to 7,672 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #5606.

UBS first reported a position in VIVO in Q2 2013 and has held it in 6 quarters since. The position peaked at $253K in Q4 2013. 161 funds tracked by Wall St. Rank hold VIVO as of Q3 2014.

  • UBS held 7,672 shares of Meridian Bioscience Inc worth $136K as of Q3 2014.
  • UBS bought 1,309 Meridian Bioscience Inc shares in Q3 2014, an estimated $25.7K.
  • Meridian Bioscience Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5606 holding.
  • UBS first reported a position in Meridian Bioscience Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Meridian Bioscience Inc position peaked at $253K in Q4 2013.
  • 161 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.